Parallel Evaluation of RLY5016 in Heart Failure - PEARL HF


The goal of the trial was to evaluate treatment with the potassium binder RLY5016 (Relypsa) compared with placebo in patients with heart failure and prior hyperkalemia that resulted in discontinuation of heart failure medications or chronic kidney disease. RLY5016 does not bind dietary potassium, but acts as a lumen sink to pull potassium from the colon.